SCHEMBL19434652

SCHEMBL19434652

Clc1ccc(CNCCCCNCc2ccc(Cl)cc2)cc1

nearest known ligand 0.91

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 6/20 0.91
SMN1; SMN2 Q16637 1/20 0.81
KDM4E B2RXH2 1/20 0.65
THRB P10828 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
HRH4 Q9H3N8 3/20 0.58
HRH3 Q9Y5N1 3/20 0.58
LMNA P02545 1/20 0.58
MAOA P21397 1/20 0.58
SIGMAR1 Q99720 2/20 0.56
POLB P06746 1/20 0.56
TMEM97 Q5BJF2 1/20 0.56
ALDH1A1 P00352 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA4 P22748 1/20 0.51
CA9 Q16790 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11672256 0.95 CHRM2 (0.83) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL11094422 0.90 CHRM2 (0.75) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL19449778 0.90 CHRM2 (0.75) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL6163688 0.87 CHRM2 (0.71) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL10151325 0.87 CHRM2 (0.71) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL9128842 0.87 SMN1; SMN2 (0.89) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL7253505 0.86 CHRM2 (0.70) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL415949 0.85 CHRM2 (0.67) CHRM2SMN1; SMN2KDM4ETHRBTDP1
Hydrochloric Acid SCHEMBL2799203 0.85 CHRM2 (0.68) CHRM2SMN1; SMN2KDM4ETHRBTDP1
SCHEMBL12332380 0.84 CHRM2 (0.66) CHRM2SMN1; SMN2KDM4ETHRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752606-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2020-08-25 US claimed
US-20200102287-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2020-04-02 US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS CHRM2 2454/4885SMN1; SMN2 3002/4885KDM4E 3521/4885
US-20200102287-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS CHRM2 2454/4885SMN1; SMN2 3002/4885KDM4E 3521/4885
US-10752606-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS CHRM2 2454/4885SMN1; SMN2 3002/4885KDM4E 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.